Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) Director Marla Persky sold 15,500 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $5.90, for a total transaction of $91,450.00. Following the transaction, the director directly owned 126,500 shares in the company, valued at approximately $746,350. The trade was a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Xeris Biopharma Trading Up 0.5%
XERS opened at $6.18 on Friday. The stock has a market capitalization of $1.07 billion, a PE ratio of 103.00 and a beta of 0.78. The firm’s fifty day moving average price is $6.10 and its 200 day moving average price is $6.59. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. Xeris Biopharma Holdings, Inc. has a 12-month low of $4.30 and a 12-month high of $10.08.
Xeris Biopharma (NASDAQ:XERS – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $83.13 million for the quarter, compared to analysts’ expectations of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. As a group, research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.
Institutional Trading of Xeris Biopharma
Analyst Upgrades and Downgrades
XERS has been the topic of several recent analyst reports. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a report on Monday, March 2nd. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $10.80.
Read Our Latest Stock Report on Xeris Biopharma
Xeris Biopharma Company Profile
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Featured Stories
- Five stocks we like better than Xeris Biopharma
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
